亚盛医药（AAPG）今日盘中大涨6.44%，引发市场广泛关注。这一显著涨幅主要源于公司近期发布的2024年全年业绩报告，以及其核心产品的强劲表现。
根据亚盛医药公布的2024年财报，公司实现营业收入9.81亿元人民币，同比大幅增长342%。这一亮眼业绩主要来自于三个方面：首先，公司从武田制药获得了1亿美元的选择权付款；其次，核心产品耐立克（奥雷巴替尼）实现2.41亿元的强劲销售，同比增长52%；最后，公司还获得了来自苏州信达的商业化许可费收入及管理费用收入。
除了财务业绩外，亚盛医药在产品开发和商业化方面也取得了重要进展。公司的新型Bcl-2选择性抑制剂APG-2575已获国家药监局药品审评中心（CDE）受理并纳入优先审评。此外，公司积极推进全球布局，耐立克已获FDA许可开展全球注册III期临床试验。这些进展不仅巩固了亚盛医药在国内市场的地位，也为其国际化战略奠定了基础，进一步提升了投资者对公司未来发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.